Ultrasensitive antigen tests are needed for early detection of numerous infectious diseases, and for surveillance and monitoring progress towards disease elimination. GHIG and IDC/LSHTM worked with the Global Good Fund and Intellectual Ventures Laboratory to understand how to improve and expand LFA technologies to a wide range of infectious and potentially non-infectious diseases with high burden in low-and middle-income countries; particularly for the neglected tropical diseases (NTDs).
An Investment Case for Lateral Flow Assays (LFAs) for Neglected Tropical Diseases (NTD)
Advanced HIV Disease (AHD) (4) Africa (3) Africa CDC (3) Antimicrobial Resistance (AMR) (2) Antiretroviral (ARV) (1) Bio banking (3) CD4 (3) Conference (1) Connectivity (1) Cost (1) COVID-19 (6) Diagnostics (2) Drones (1) Early Infant Diagnosis (EID) (5) Evaluations (1) Global Diseases (1) Global Health (1) Global Health Continuing Professional Development (GHCPD) (1) Guidance (1) Health Systems (1) Hepatitis (2) HIV (7) Laboratory Medicine (1) Lateral Flow Assays (LFAs) (2) Massive open online course (MOOC) (1) Neglected Tropical Diseases (NTD) (3) Outbreaks (1) PAHO (1) Panels (1) POINT-OF-CARE (2) Point-of-Care (POC) (3) Policy (1) Quality (1) QUALITY ASSURANCE (QA) (3) Serology (4) Supply Chain (1) Syphilis (1) VIRAL LOAD (VL) (8) WHO (1) Zika (3)
ASLM Conference Coordinator
GlobalHealthIGSeptember 10, 2019
Global DiseasesInnovations & DiagnosticsTechnical Assistance
Evaluation of Zika Singleplex and Multiplex diagnostics for clinical and surveillance use
Health Systems StrengtheningInnovations & DiagnosticsWorkshops